Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

VRAX vs REVB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

REVB Captures Overall Composite Edge (34.4 SELL vs 41.7 SELL), While VRAX Leads 3–1 on Growth & Valuation Pillars

REVB Overall Winner 6-Pillar Tally: VRAX 3 – 1 REVB (2 Tie) Matrix Metrics: VRAX 4 – 4 REVB

As of Nov 17, 2026, Revelation Biosciences, Inc. (REVB) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (34.4/100 SELL vs. 41.7/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples), while VRAX wins 3–1 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.43 (N/M Forward P/E, -51515.2% operating margin) versus REVB at $3.83 (0.9x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. REVB 34.4/100 SELL), REVB captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51515.2% operating margin) and revenue trajectory (+0.0% vs. +684.9% YoY).
  • Defensive Composite Rating Caution: Although REVB compares more favorably head-to-head, both VRAX (41.7/100 SELL) and REVB (34.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VRAX vs REVB
VRAX NASDAQ
Virax Biolabs Group Limited Ordinary Shares
In Vitro & In Vivo Diagnostic Substances
$0.43
-4.02% 1D
Market Cap $823,939
TTM Revenue $12,423
Forward P/E N/M
Beta / 30D Vol -9.42β · 161% Vol
Unified Composite Score
41.7 / 100 SELL
Tech 25.0 Fund 44.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -30.6%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.97 · SMA50: $1.70
REVB NASDAQ Head-to-Head Winner
Revelation Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$3.83
+0.13% 1D
Market Cap $2.4M
TTM Revenue N/A
Forward P/E 0.9x
Beta / 30D Vol 2.97β · 2364% Vol
Unified Composite Score
34.4 / 100 SELL
Tech 8.0 Fund 23.0 Flow 50.0 Mom 11.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (117.3% over 20 days), RSI 59
RSI-14: 58.7 · SMA20: $3.93 · SMA50: $2.13

6-Pillar Scorecard Institutional Category Breakdown (VRAX 3 – 1 REVB)

Columns: Metric · VRAX · REVB
1. Valuation Multiples REVB
Forward P/E N/M 0.9x
Trailing P/E N/M 0.9x
PEG Ratio N/M N/M
EV / Revenue 66.3x N/M
2. Growth & Scale VRAX
Revenue Growth (YoY) +684.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $12,423 N/A
Market Cap $823,939 $2.4M
3. Profitability & Quality VRAX
Gross Margin 61.9% N/A
Operating Margin -51515.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -78.6% -133.4%
4. Balance Sheet & Cash Flow VRAX
Cash Generation (TTM) -$6.0M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $13.08 Book/Sh · -78.6% ROE $10.58 Book/Sh · -133.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VRAX (4) vs REVB (4)
Institutional Metric VRAX REVB Criterion Row Edge
Market Capitalization
Scale
$823,939 $2.4M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M 0.9x Lower Multiple REVB
Forward P/E Ratio
Valuation
N/M 0.9x Lower Multiple REVB
Revenue Growth (YoY)
Growth
+684.9% +0.0% Higher Growth VRAX
Operating Margin (TTM)
Profitability
-51515.2% 0.0% Higher Margin REVB
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-78.6% -133.4% Higher ROE VRAX
52-Week Range Position
Momentum
2% ($0–$13) 78% ($0–$5) Stronger Trend REVB
Beta / 30D Volatility
Risk Regime
-9.42β · 161% Vol 2.97β · 2364% Vol Lower Realized Risk VRAX
Unified Institutional Score
Composite Signal
41.7 / 100 (SELL) 34.4 / 100 (SELL) Higher Composite VRAX
Trailing 12M Revenue (USD)
Operating Scale
$12,423 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
61.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 66.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$6.0M EBITDA ($13.08 Book/Sh · -78.6% ROE) N/A ($10.58 Book/Sh · -133.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon REVB +784.33 pp
VRAX: -69.29% · REVB: +715.04%
3M Horizon REVB +331.07 pp
VRAX: -86.48% · REVB: +244.59%
6M Horizon REVB +232.2 pp
VRAX: +39.16% · REVB: +271.36%
1Y Horizon REVB +337.89 pp
VRAX: -12.42% · REVB: +325.47%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs REVB. Trailing 12-month operating profitability (VRAX -51515.2% vs REVB 0.0%) and valuation multiples (VRAX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.

VRAX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$12,423
Gross Margin61.9%
Op. Margin-51515.2%
ROE / Fwd P/E-78.6% · N/M
REVB ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-133.4% · 0.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VRAX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VRAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
REVB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact REVB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VRAX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $823,939 market capitalization and -51515.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
REVB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VRAX vs REVB Key Questions & Quantitative Answers

As of Nov 17, 2026, Revelation Biosciences, Inc. (REVB) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (34.4/100 SELL vs. 41.7/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples), while VRAX wins 3–1 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.43 (N/M Forward P/E, -51515.2% operating margin) versus REVB at $3.83 (0.9x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. REVB 34.4/100 SELL), REVB captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51515.2% operating margin) and revenue trajectory (+0.0% vs. +684.9% YoY). Defensive Composite Rating Caution: Although REVB compares more favorably head-to-head, both VRAX (41.7/100 SELL) and REVB (34.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VRAX leads the Growth & Scale pillar: VRAX posts +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin), compared with REVB at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VRAX generates $12,423 in USD-normalized revenue versus N/A for REVB. In operating R&D and SG&A reinvestment, VRAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REVB.

REVB screens cheaper on headline valuation multiples. VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 66.3x EV/Revenue (unreported EBITDA margin), whereas REVB trades at 0.9x Forward P/E, 0.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRAX (-78.6% ROE) versus REVB (-133.4% ROE) capital efficiency.

In options market volatility and institutional positioning, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.42β · 161% Vol realized risk). By comparison, REVB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.97β · 2364% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.